## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.05 indicates fundamental undervaluation. Quality metrics strong (ROE 82%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-5.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($314.23)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. A Closer Look at Amgen (AMGN) Valuation After Its 12-Month 28% Share Price Gain**
- Source: Simply Wall Street | 20251205T190742 | Neutral | Relevance: 100%
- Amgen (AMGN) has seen a strong year, with its stock price gaining 28% over the past 12 months, outperforming many healthcare peers. While the stock's recent performance suggests positive momentum, a valuation narrative indicates it might be 5.4% overvalued compared to a fair value estimate of $322.88, despite its PE ratio appearing cheaper than the peer average. The article explores whether its significant gains and current valuation are justified given its robust pipeline and potential risks from drug pricing pressures.

**2. Amgen (AMGN) Stock Hits New 52â€‘Week High as Obesity Drug Bets and Analyst Upgrades Fuel 2025 Rally**
- Source: ts2.tech | 20251203T223558 | Bullish | Relevance: 100%
- Amgen (NASDAQ: AMGN) reached a new 52-week high of $345.95 on December 3, 2025, driven by strong Q3 earnings, the promising obesity drug MariTide, and analyst upgrades. While the stock's year-to-date gain is over 34%, analysts express caution due to valuation concerns and upcoming patent expirations, balancing the optimism around its pipeline and diversified growth. The future performance heavily relies on MariTide's clinical trial outcomes and the company's ability to navigate competitive and regulatory pressures.

**3. BMO Capital Adjusts Price Target on Amgen to $372 From $335, Maintains Outperform Rating**
- Source: MarketScreener | 20251203T103400 | Bullish | Relevance: 100%
- BMO Capital has increased its price target for Amgen to $372 from $335, while reiterating an Outperform rating on the stock. This adjustment reflects continued analyst confidence in the biotechnology group. The article also provides a snapshot of Amgen's stock performance and other recent news related to the company including insider transactions and FDA approvals.

**4. Tema Etfs LLC Has $3.62 Million Stock Holdings in Amgen Inc. $AMGN**
- Source: MarketBeat | 20251205T134359 | Bullish | Relevance: 100%
- Tema Etfs LLC increased its holdings in Amgen Inc. by 33.3%, now owning 12,977 shares valued at $3.623 million. Amgen reported strong quarterly earnings, beating EPS estimates and achieving a 12.4% revenue increase, while also declaring a $2.38 quarterly dividend. Analysts currently rate Amgen as a "Moderate Buy" with a consensus target price of $335.65.

**5. First Trust Advisors LP Sells 21,347 Shares of Amgen Inc. $AMGN**
- Source: MarketBeat | 20251205T101439 | Somewhat-Bullish | Relevance: 100%
- First Trust Advisors LP reduced its stake in Amgen Inc. by 3.8% in the second quarter, selling 21,347 shares and now owning 534,829 shares valued at $149.33 million. Other institutional investors like Brighton Jones LLC and Deutsche Bank AG have adjusted their positions in the medical research company. Amgen recently reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $2.38 per share.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 4, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |
| 2025-11-14 | Piper Sandler | $381 | $342 | +11% |
| 2025-11-06 | Cantor Fitzgera | $315 | $305 | +3% |
| 2025-11-05 | Morgan Stanley | $329 | $333 | -1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-03 | BMO Capital | main | Outperform |
| 2025-11-14 | Piper Sandler | main | Overweight |
| 2025-11-06 | Cantor Fitzgera | main | Neutral |
| 2025-11-05 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.4% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +8%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 1.05 suggests fair value with growth premium. Forward P/E 15.0x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (4 raises, avg +8%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $179.3B |
| Beta | 0.45 |
| 52W Range | $257.05 - $346.38 |
| Short Interest | 2.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.05 |
| Forward P/E | 15.0 |
| Current P/E | 15.5 |
| YoY Growth | 3.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.2% to -4.2% (-5.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.2pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). MACD histogram bearish (-2.05), momentum weakening. RSI neutral at 51. OFD pattern: -FTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.16% (CS: 17) | Weak |
| RSI_14 | 50.9 | Neutral |
| MACD Histogram | -2.05 | Bearish |
| vs SMA20 | 0.977x | Below |
| vs SMA50 | 1.057x | Above |
| vs SMA200 | 1.112x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $329.89
- **Stop Loss:** $314.23 (4.7% risk)
- **Target:** $361.21 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 31
- **Position Value:** $10,226.59
- **Portfolio %:** 10.23%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*